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Background: As time evolved, traditional Chinesemedicine (TCM) became integrated into
the global medical system as complementary treatments. Some essential TCM herbs
started to play a limited role in clinical practices because of Western medication
development. For example, Fuzi (Aconiti Lateralis Radix Praeparata) is a toxic but
indispensable TCM herb. Fuzi was mainly used in poor circulation and life-threatening
conditions by history records. However, with various Western medication options for
treating critical conditions currently, how is Fuzi used clinically and its indications in modern
TCM are unclear. This study aimed to evaluate Fuzi and Fuzi-based formulas in modern
clinical practices using artificial intelligence and data mining methods.
Methods: This nationwide descriptive study with market basket analysis used a cohort
selected from the Taiwan National Health Insurance database that contained one million
national representatives between 2003 and 2010 used for our analysis. Descriptive
statistics were performed to demonstrate the modern clinical indications of Fuzi.
Market basket analysis was calculated by the Apriori algorithm to discover the
association rules between Fuzi and other TCM herbs.
Results: A total of 104,281 patients using 405,837 prescriptions of Fuzi and Fuzi-based
formulas were identified. TCM doctors were found to use Fuzi in pulmonary (21.5%),
gastrointestinal (17.3%), and rheumatologic (11.0%) diseases, but not commonly in
cardiovascular diseases (7.4%). Long-term users of Fuzi and Fuzi-based formulas often
had the following comorbidities diagnosed by Western doctors: osteoarthritis (31.0%),
peptic ulcers (29.5%), hypertension (19.9%), and COPD (19.7%). Patients also used
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drugs, β-blockers, calcium channel blockers, and aspirin. Through market basket analysis,
for the first time, we noticed many practical Fuzi-related herbal pairs such as Fuzi–Hsihsin
(Asari Radix et Rhizoma)–Dahuang (Rhei Radix et Rhizoma) for neurologic diseases and
headache.
Conclusion: For the first time, big data analysis was applied to uncover themodern clinical
indications of Fuzi in addition to traditional use. We provided necessary evidence on the
scientific use of Fuzi in current TCM practices, and the Fuzi-related herbal pairs discovered
in this study are helpful to the development of new botanical drugs.
Keywords: aconitum, clinical epidemiology, data mining, Fuzi, market basket analyses
INTRODUCTION
Traditional and complementary medicine (T&CM) has played an
increasingly significant role in the global medical system. The
World Health Organization (WHO) started to facilitate the
integration of T&CM into national health systems in member
states, produced guidelines for T&CM complying with
international standards, stimulated strategic research into
T&CM, and advocated the rational use of T&CM through
clinical evidence (World Health Organization, 2013).
Traditional Chinese Medicine (TCM) is the most popular
T&CM system worldwide, especially in Asia and North
America. Most Western doctors and researchers come to
know the clinical indications of TCM herbs from TCM books
such as Shen Nong Ben Cao Jing and Shang Han Lun (Tai et al.,
2015). However, modern clinical indications of TCM herbs might
differ from those of ancient times because the current TCM
doctors approach patients with innovative strategies using TCM
herbs in combination with Western medications (Chen et al.,
2015).
For example, Fuzi (Aconiti Lateralis Radix Praeparata) has
been widely used in TCM for more than 2000 years (Nyirimigabo
et al., 2015). In TCM, Fuzi and Fuzi-based formulas were
prescribed to improve circulation in patients with cold
extremities, weak pulse, general weakness, and fatigue
(Singhuber et al., 2009). The applications of Fuzi were
advocated in Shang Han Lun, which was an essential TCM
book written by Zhon-Ging Zhang in the Eastern Han
Dynasty around 150–209 AD. Zhang introduced some Fuzi-
based formulas, including Sini Tang (Aconiti Lateralis Radix
Praeparata, Zingiberis Rhizoma, and Glycyrrhizae Radix et
Rhizoma) and Jenwu Tang (Aconiti Lateralis Radix Praeparata,
Poria, Paeoniae Rubra Radix, Zingiberis Rhizoma, and
Atractylodis Macrocephalae Rhizoma) (Zhang et al., 1999).
After then, these famous Fuzi-based formulas have been used
clinically, especially for the critical condition, in TCM for
thousands of years. The use of Fuzi was also advocated by
modern TCM doctors such as Hai-Ha Ni in the United States
and Bu-Tao Chang in Taiwan (Tai et al., 2015).
Fuzi was also used in Ayurvedic and Kampo medicine to treat
several clinical conditions such as neuralgia, polyuria, poor
circulation, heart failure (HF), and even impotence (Tai et al.,
2015). In Japan, some famous Fuzi-based formulas were directly
adopted by Kampo medicine. For example, Shinbuto resembled
Jenwu Tang and Shigyakuto was derived from Sini Tang. In
addition, Kampo medicine doctors introduced some innovative
Fuzi-based commercial formulas for new clinical indications,
such as Gosha-jinki-gan (Aconiti Lateralis Radix Praeparata,
Rehmanniae Radix, Achyranthis Bidentatae Radix, Corni
Sarcocarpium, Dioscoreae Rhizoma, Plantaginis Semen, Alisma
Rhizoma, Poria, Moutan Radicis Cortex, and Cinnamomi
Cortex) for lymphedema (Abe, 2002). These applications
supported the importance of Fuzi, which was not only limited
to TCM, in modern medical system.
Although the therapeutic effect of Fuzi and Fuzi-based
formula are widely recognized among TCM doctors and
therapists, the toxicity of Fuzi has always been the main
concern for their applications and further promotion (Lu
et al., 2010). The major pharmacologic components of Fuzi
are diester-diterpenoid alkaloids (DDAs, including aconitine,
mesaconitine, and hypaconitine) and monoester-diterpenoid
alkaloids (MDAs, including benzoylaconine,
benzoylmesaconine, and benzoylhypaconine), which might
provoke cardiac arrhythmias (Csupor et al., 2009). More than
600 cases of aconitum poisoning were published worldwide,
mostly in China and Hong Kong (Chan, 2002). Furthermore,
even in Asia,Western medicine has significantly replaced TCM in
the treatment of critical conditions in recent years. Therefore, it is
not known whether the clinical indications of Fuzi have changed
over time.
In Taiwan, TCM has been formally adopted into the Taiwan
National Health Insurance (NHI) system since 1996 (Chu et al.,
2015), and the system reimburses more than 95% of TCM
services. Given that one-third of the Taiwanese population
uses TCM (Huang C. W. et al., 2018), the Taiwan NHI
database is a unique engine to generate evidence-based results
to improve practices, policy-making, and TCM integrated with
Western medicine.
Analyzing the Taiwan NHI database, previous epidemiologic
TCM studies have successfully observed the effectiveness and
adverse effects of TCM formulas on a specific single disease (Lai
et al., 2013; Chang et al., 2016). At present, there is no study using
a well-documented database to explore the modern clinical
applications of single TCM herbs or well-known formulas, or
to expand their clinical indications for treating diseases or
syndromes. To reveal the essence and art of the TCM, we
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aimed to demonstrate the use of artificial intelligence (AI) and
data mining methods to shed new light on TCM use in Western
medicine predominant populations. Herein, the Fuzi and Fuzi-
based formulas are as representatives.
METHODS
Data Source
This retrospective cohort study using a longitudinal cohort of
Taiwan NHI database comprises a randomly sampled
representative database of one million people from all NHI
enrollees alive in 2000 (National Health Insurance
Administration, 2014). The single-payer NHI program has
enrolled more than 99% of the 23 million people in Taiwan’s
population, which was launched in Taiwan in 1995 (Huang
et al., 2016). The Taiwan NHI database contains the
beneficiaries’ medical records, such as demographic data,
inpatient records, outpatient prescriptions, and expenditure
for healthcare services. The Taiwan NHI database is a de-
linked and anonymized database, which well protects the
privacy of patient information. TCM products processed by
standard pharmacopeial methods were commonly prescribed
in the healthcare system in Taiwan. Moreover, TCM doctors in
Taiwan began to use the International Classification of
Diseases Revision, Ninth Revision, Clinical Modification
(ICD-9-CM) codes for their clinical diagnosis since May
2002. Therefore, we used a subset of the Taiwan NHI
database from 2003 to 2010 for further analysis. This study
was approved by the Institutional Review Board of Antai
Medical Care Cooperation Antai-Tian-Sheng Memorial
Hospital (protocol number: 18-015-C; approval date: Feb.
21st, 2018).
Fuzi and Fuzi-Based Formulas
We searched for prescriptions of Fuzi and Fuzi-based formulas
from outpatient medical claims with the specific drug codes in the
cohort between January 2003 and December 2010
(Supplementary Table S1). There were four famous Fuzi-
based formulas, including Sini Tang, Jenwu Tang, Mahuang-
Fuzi-Hsihsin Tang (Ephedra Herba, Aconiti Lateralis Radix
Praeparata, and Asari Radix et Rhizoma), and Fuzi-Lizhong
Tang (Aconiti Lateralis Radix Praeparata, Ginseng Radix,
Zingiberis Rhizoma, Atractylodis Macrocephalae Rhizoma, and
Glycyrrhizae Radix et Rhizoma), commercially available in the
Taiwan NHI system. Other commercially unavailable Fuzi-based
formulas have not been recorded in the Taiwan NHI system.
Descriptive Study Design
First, the prescription numbers of Fuzi and Fuzi-based
formulas and their growth rate were estimated. In Taiwan,
only Western medicine doctor can prescribe Western
medications. Similarly, only TCM doctors can prescribe
TCM drugs. To specify the primary diagnosis documented
by the TCM doctors prescribing Fuzi, we grouped the primary
ICD-9-CM diagnosis as diagnostic categories for analysis
(Supplementary Table S2). The diagnostic categories were
divided into 19 conditions, including headache, cancer,
infection, benign tumor, unspecific complaints, as well as
neurological, psychological, rheumatological, urological,
obstetrical/gynecological, hematological, dermatological,
cardiovascular, endocrine, pulmonary, gastrointestinal,
musculoskeletal, sensory organs, and male reproductive
systems disorders.
Second, the third quartile patients who experienced higher
prescription numbers or prescription duration were defined as
the long-term users of Fuzi or Fuzi-based formulas. To identify
long-term users’ underlying comorbidities diagnosed by
Western medicine doctors, we analyzed the selected
corresponding ICD-9-CM codes in outpatient medical claims
before the prescription date of Fuzi or Fuzi-based formulas
(Supplementary Table S3). The medical comorbidities
included hypertension, DM, cerebrovascular disease, HF,
ischemic heart disease, cardiac arrhythmias, hyperlipidemia,
chronic obstructive pulmonary disease (COPD), chronic
kidney disease (CKD), chronic liver disease, esophageal
disease, peptic ulcers, thyroid disease, rheumatoid arthritis
(RA), ankylosing spondylitis (AS), systemic lupus
erythematosus (SLE), osteoarthritis, and cancer.
Finally, the common Western medications were evaluated,
including aspirin, clopidogrel, lipid-lowering agents (statins,
fibrates, and other lipid-lowering agents), xanthine oxidase
inhibitors, uricosuric agents, colchicine, β-blockers, calcium
channel blockers (CCBs), angiotensin-converting enzyme
inhibitors (ACEI)/angiotensin receptor blockers (ARBs),
H2-receptor antagonists, proton pump inhibitors (PPIs),
nonsteroidal anti-inflammatory drugs (NSAIDs),
metformin, sulfonylurea, insulin, COPD inhalants,
thyroxine, and α-adrenoreceptor antagonists
(Supplementary Table S4). To identify the co-use of
Western medications with Fuzi, we identified the
mentioned Western medications by the corresponding
anatomical therapeutic chemical (ATC) codes.
Market Basket Analysis
Market basket analysis, a data mining technique introduced by
Agrawal et al., is frequently used to discover the rules of
association between sets of items in large databases
(Agrawal et al., 1993). In our study, 442 kinds of TCM
single herbs used in the Taiwan NHI system were evaluated
by the market basket analysis to reveal their combination
principle of Fuzi, so-called Fuzi-related pairs. The
mentioned TCM herbal drugs with significant findings,
including their Latin names and scientific names, were
listed in Supplementary Table S5.
The association rules derived from market basket analysis
were demonstrated in the following three measures: support,
confidence, and lift (Tan et al., 2005). 1) The support was the
relative frequency that the rule showed up in the given dataset.
2) The confidence measured the reliability of the inference
made by a rule. For example, an association rule X (antecedent
factor) to Y (consequent factor) was established by the estimate
of the conditional probability of Y given X (antecedent
confidence) or X given Y (consequent confidence), and high
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confidence indicated a strong association rule. This study
generated frequent TCM pairs that have the support of at
least 5%. 3) The lift was the likelihood of prescribing both
drugs compared with a single drug. Lift value above one means
there was a positive correlation between the two drugs. The
higher the lift value, the more likely the two drugs were to be
prescribed together.
Statistical Analyses
Demographic statistics were demonstrated as means ± standard
deviation, median, interquartile, or number (percentages). SAS
version 9.4 (SAS Institute Inc, Cary, NC, United States) was used
for data collection, and statistical analyses. Market basket
analysis was calculated by the Apriori algorithm using
Python version 3.7.
FIGURE 1 | National trends in the prescriptions of Fuzi and Fuzi-based formulas during 2003–2010.
TABLE 1 | Clinical indications of prescriptions of Fuzi and Fuzi-based formulas from TCM doctors in systematic categories.
Category Fuzi
n = 179,653, n (%)
Sini Tang
n = 104,674, n (%)
Jenwu Tang




n = 14,090, n (%)
n = 42,592, n (%)
Gastrointestinal system 35,336 (19.7) 17,217 (16.4) 8,889 (12.7) 3,263 (7.7% 6,414 (45.5)
Pulmonary system 32,119 (17.9) 14,278 (13.6) 14,539 (20.8) 25,876 (60.8) 1,468 (10.4)
Rheumatology 21,527 (12.0) 15,553 (14.9) 4,299 (6.2) 3,018 (7.1) 812 (5.8)
Neurology 17,470 (9.7) 12,695 (12.1) 8,613 (12.3) 1771 (4.2) 879 (6.2%)
Gynecology 15,739 (8.8) 12,738 (12.2) 4,212 (6.0) 1,607 (3.8) 1,563 (11.1)
Cardiovascular system 13,585 (7.6) 7,941 (7.6) 7,685 (11.0) 762 (1.8) 541 (3.8)
Headache 8,359 (4.7) 4,420 (4.2) 4,427 (6.3) 2,357 (5.5) 307 (2.2)
Dermatology 6,767 (3.8) 4,267 (4.1) 4,186 (6.0) 988 (2.3) 423 (3.0)
Urology 5,724 (3.2) 2,324 (2.2) 3,689 (5.3) 439 (1.0) 354 (2.5)
Endocrine system 5,499 (3.1) 2,797 (2.7) 1,692 (2.4) 466 (1.1) 267 (1.9)
Musculoskeletal system 4,928 (2.7) 4,211 (4.0) 1,419 (2.0) 1,010 (2.4) 314 (2.2)
Sensory organs 3,944 (2.2) 1960 (1.9) 3,446 (4.9) 414 (1.0) 211 (1.5)
Unspecific complaints 1949 (1.1) 1,208 (1.2) 552 (0.8) 155 (0.4) 116 (0.8)
Cancer 1,562 (0.9) 597 (0.6) 434 (0.6) 106 (0.2) 13 (0.1)
Psychology 1704 (0.9) 730 (0.7) 578 (0.8) 118 (0.3) 102 (0.7)
Male reproductive system 1,289 (0.7) 410 (0.4) 664 (1.0) 91 (0.2) 37 (0.3%)
Hematology 883 (0.5) 671 (0.6) 326 (0.5) 45 (0.1) 57 (0.4)
Infectious diseases 843 (0.5) 420 (0.4) 130 (0.2) 62 (0.1) 182 (1.3)
Benign tumors 426 (0.2) 237 (0.2) 84 (0.1) 44 (0.1) 30 (0.2)
Corresponding ICD-9-CM codes of each category were listed in Supplementary Table S2. The sensory system includes ophthalmology and otolaryngology.
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RESULTS
Clinical Demographics and the
Prescriptions of Fuzi and Fuzi-Based
Formulas
A total of 104,281 patients using 405,837 prescriptions of Fuzi
and Fuzi-based formulas were identified between January 2003
and December 2010. Among the users, 11.7% were older adults
(≥65 years old), 9.5% were children or adolescents (≤18 years
old). The mean age of the users was 41.2 ± 18.0 years. The users
received 1.4 ± 0.7 types of Fuzi prescriptions during the
evaluation period, and the average prescription number in
each patient was 3.9 ± 7.2 (median, 2; third quartile, 4). The
average duration of the prescriptions was 304.3 ± 589.0 days
(median, 8; third quartile, 286). The number of long-term users
(number of prescriptions >4) was 28,978 patients, including
12.5% older adults and 8.3% of children or adolescents.
TABLE 2 | Underlying comorbidities diagnosed by Western medicine doctors of patients who long-term used fuzi and fuzi-based formulas.
Comorbidities Fuzi and
Fuzi-based formulas
n = 28,978, n (%)
Fuzi
n = 20,233, n (%)
Sini Tang
n = 15,286, n (%)
Jenwu Tang
n = 11,177, n (%)
Mahuang-Fuzi-Hsihsin
Tang
n = 7,549, n (%)
Fuzi-Lizhong Tang
n = 2,820, n (%)
Osteoarthritis 8,971 (31.0) 6,867 (33.9) 5,253 (34.4) 4,291 (38.4) 2,126 (28.2) 968 (34.3)
Peptic ulcers 8,543 (29.5) 6,755 (33.4) 5,108 (33.4) 4,119 (36.9) 2,379 (31.5) 1,173 (41.6)
Hypertension 5,768 (19.9) 4,242 (21.0) 3,006 (19.7) 2,912 (26.1) 1,156 (15.3) 580 (20.6)
COPD 5,695 (19.7) 4,269 (21.1) 3,099 (20.3) 2,754 (24.6) 1792 (23.7%) 625 (22.2%)
Hyperlipidemia 4,740 (16.4) 3,635 (18.0) 2,737 (17.9) 2,428 (21.7) 1,088 (14.4) 496 (17.6)
Chronic liver disease 4,717 (16.3) 3,641 (18.0) 2,773 (18.1) 2,229 (19.9) 1,203 (15.9) 572 (20.3)
Diabetes mellitus 3,002 (10.4) 2,260 (11.2) 1741 (11.4) 1,527 (13.7) 642 (8.5) 299 (10.6)
Esophageal disease 2,577 (8.9) 2084 (10.3) 1,666 (10.9) 1,435 (12.8) 758 (10.0) 373 (13.2)
Thyroid disease 2,194 (7.6) 1776 (8.8) 1,396 (9.1) 1,093 (9.8) 591 (7.8 296 (10.5)
RA, SLE, or AS 1901 (6.6) 1,529 (7.6) 1,221 (8.0) 982 (8.8) 539 (7.1) 333 (8.3)
Cerebrovascular disease 1871 (6.5) 1,385 (6.8) 1,041 (6.8) 1,054 (9.4) 383 (5.1) 168 (6.0)
Cardiac arrhythmias 1727 (6.0) 1,389 (6.9) 1,057 (6.9) 1,006 (9.0) 515 (6.8) 239 (8.5)
Ischemic heart disease 1,505 (5.2) 1,195 (5.9) 893 (5.8) 863 (7.7) 343 (4.5) 163 (5.8)
Cancer 1,181 (4.1) 915 (4.5) 662 (4.3) 586 (5.2) 270 (3.6) 128 (4.5)
Heart failure 744 (2.6) 576 (2.8) 421 (2.8) 458 (4.1) 159 (2.1) 72 (2.6)
Chronic kidney disease 449 (1.6) 324 (1.6) 207 (1.4) 280 (2.5) 77 (1.0) 57 (2.0)
Corresponding ICD-9-CM codes of each disease were listed inSupplementary Table S3. AS  ankylosing spondylitis; COPD  chronic obstructive pulmonary disease; RA  rheumatoid
arthritis; SLE  systemic lupus erythematosus.
TABLE 3 | Common Western medications prescribed by Western medicine doctors in patients who long-term use Fuzi and Fuzi-based formulas.




















NSAIDs 19,648 (67.8) 14,545 (71.9) 11,522 (75.4) 8,516 (76.6) 5,767 (76.4) 2,184 (77.4)
H2-receptor antagonist 8,663 (29.9) 6,669 (33.0) 5,523 (36.1) 4,070 (36.6) 2,642 (35.0) 1,134 (40.2)
β-Blockers 6,930 (23.9) 5,306 (26.2) 4,201 (27.5) 3,529 (31.7) 1788 (23.7) 786 (27.9)
CCBs 6,306 (21.8) 4,810 (23.8) 3,692 (24.2) 3,264 (29.4) 1,538 (20.4) 697 (24.7)
ACEI/ARB 4,732 (16.3) 3,603 (17.8) 2,789 (18.2) 2,485 (22.4) 1,161 (15.4) 523 (18.5)
Aspirin 4,204 (14.5) 3,235 (16.0) 2,553 (16.7) 2,169 (19.5) 1,038 (13.8) 452 (16.0)
Lipid-lowering agents 3,699 (12.8) 2,798 (13.8) 2,235 (14.6) 1881 (16.9) 915 (12.1) 401 (14.2)
Sulfonylurea 3,162 (10.9) 2,401 (11.9) 1953 (12.8) 1,608 (14.5) 829 (11.0) 359 (12.7)
Metformin 3,076 (10.6) 2,334 (11.5) 1921 (12.6) 1,574 (14.2) 788 (10.4) 367 (13.0)
Proton pump inhibitor 2,354 (8.1) 1858 (9.2) 1,564 (10.2) 1,234 (11.1) 680 (9.0) 316 (11.2)
α-Adrenoreceptor antagonists 1855 (6.4) 1,417 (7.0) 1,124 (7.4) 968 (8.7) 465 (6.2) 209 (7.4)
COPD inhalants 1,637 (5.6) 1,255 (6.2) 940 (6.1) 864 (7.8) 571 (7.6) 168 (6.0)
Colchicine 1,315 (4.5) 1,019 (5.0) 819 (5.4) 649 (5.8) 346 (4.6) 138 (4.9)
Uricosuric agents 1,141 (3.9) 896 (4.4) 701 (4.6) 597 (5.4) 296 (3.9) 126 (4.5)
XOIs 814 (2.8) 626 (3.1) 496 (3.2) 406 (3.7) 197 (2.6) 97 (3.4)
Insulin 675 (2.3) 514 (2.5) 393 (2.6) 399 (3.6) 159 (2.1) 77 (2.7)
Thyroxine 615 (2.1) 484 (2.4) 396 (2.6) 328 (3.0) 161 (2.1) 70 (2.5)
Clopidogrel 467 (1.6) 366 (1.8) 278 (1.8) 253 (2.3) 96 (1.3) 57 (2.0)
Corresponding ATC codes of each medication were listed in Supplementary Table S4. ACEI  angiotensin-converting enzyme inhibitors; ARB  angiotensin receptor blockers;
CCBs  calcium channel blockers; NSAIDs  nonsteroidal anti-inflammatory drugs; XOIs  xanthine oxidase inhibitors.
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The total prescriptions of Fuzi and Fuzi-based formulas increased
annually, from 28,578 prescriptions in 2003 to 75,058 prescriptions in
2010 (Figure 1). Among the prescriptions, 43.7%were Fuzi as a single
component, and the others were Fuzi-based formulas. A small
fraction of prescriptions (2,324, 1.3%) used Fuzi in addition to the
Fuzi-based formulas. According to the number of prescriptions, the
prescriptions of Fuzi-based formula from high to low were Sini Tang,
Jenwu Tang, Mahuang-Fuzi-Hsihsin Tang, and Fuzi-Lizhong Tang.
The compound annual growth rate of prescriptions of Fuzi, Sini
Tang, Jenwu Tang, Mahuang-Fuzi-Hsihsin Tang, and Fuzi-Lizhong
Tang was 14.3, 15.2, 15.6, 14.8, and 13.8%, respectively.
Of the total number of prescriptions, Fuzi and Fuzi-based
formulas were commonly used in clinical conditions including
pulmonary (21.5%), gastrointestinal (17.3%), rheumatologic
(11.0%), neurologic (10.1%), and gynecologic (8.7%) diseases
(Figure 2). Of surprise, Fuzi and Fuzi-based formulas were
not commonly used in cardiovascular diseases (7.4%) and
cancer complementary treatment (0.7%). The details in the
prescriptions of Fuzi and Fuzi-based formulas were listed in
Table 1.
Clinical Comorbidities and Related Western
Medications
From the viewpoint of Western medicine, the most frequent
comorbidities of long-term Fuzi or Fuzi-based formulas users
were osteoarthritis (31.0%), gastric or peptic ulcers (29.5%),
hypertension (19.9%), COPD (19.7%), hyperlipidemia (16.4%),
and chronic liver diseases (16.3%) (Table 2). The users of Jenwu
Tang experienced the highest prevalence of osteoarthritis (38.4%),
COPD (24.6%), hypertension (26.1%), DM (13.7%), and
cerebrovascular disease (9.4%) among all users of Fuzi-based
formulas (Table 2). The users of Fuzi and Fuzi-based formulas
often took Western medications such as NSAIDs (67.8%), H2-
receptor antagonists (29.9%), β-blockers (23.9%), CCBs (21.8%),
ACEI/ARBs (16.3%), and aspirin (14.5%) (Table 3). These results
showed that long-term Fuzi users suffered from some underlying
comorbidities and took related Western medications.
Fuzi-Related Herbal Pairs
Fuzi may be combined with other TCM herbs according to the
knowledge and experience of the TCM doctors. We analyzed the co-
prescription TCM single herbs with Fuzi. Of total Fuzi prescriptions,
the top 10 Fuzi-related herbal pairs were Fuzi–Dahuang (Rhei Radix
et Rhizoma) (16.5%), Fuzi–Hsihsin (Asari Radix et Rhizoma)
(15.9%), Fuzi–Ganjiang (Zingiberis Rhizoma) (15.5%), Fuzi–Fuling
(Poria) (13.8%), Fuzi–Baizhu (AtractylodisMacrocephalae Rhizoma)
(10.3%), Fuzi–Quizhi (Cinnamomi Ramulus) (10.1%),
Fuzi–Huangqi (Astragali Radix) (9.0%), Fuzi–Banxia (Pinelliae
Rhizoma) (8.3%), Fuzi–Rouqui (Cinnamomi Cortex) (8.0%), and
Fuzi-Gancao (Glycyrrhizae Radix et Rhizoma) (7.1%) (The scientific
names of these herbs were listed in Supplementary Table S5). The
rank of the top 10 TCM herbs prescribed in combination with Fuzi
was altered in the classified subgroups of specific clinical conditions.
Herein, we identified Fuzi-related single herbal pairs in six specific
clinical conditions (Table 4).
TABLE 4 | Top 10 Fuzi–single TCM herbal pairs prescribed by TCM doctors to treat patients with six specific clinical conditions.
1. Pulmonary diseases, total prescriptions n = 29,621, n (%)
Hsihsin Ganjiang Mahuang Dahuang Quizhi Fuling Jiegeng Gancao Banxia Huangqi
8,165 (27.6%) 5,012 (16.9%) 4,347 (14.7%) 3,230 (10.9%) 3,077 (10.4%) 3,072 (10.4%) 2,750 (9.3%) 2,567 (8.7%) 2,553 (8.6%) 2,465 (8.3%)
2. Gastrointestinal diseases, total prescriptions n = 33,013, n (%)
Dahuang Hsihsin Fuling Ganjiang Banxia Baizhu Sharen Quizhi Rouqui Huangqi
9,581 (29.0%) 6,861 (20.8%) 6,375 (19.3%) 5,616 (17.0%) 5,204 (15.8%) 3,201 (9.7%) 3,102 (9.4%) 2,480 (7.5%) 2,458 (7.4%) 2,414 (7.3%)
3. Rheumatological diseases, total prescriptions n = 19,265, n (%)
Quizhi Baizhu Fuling Ganjiang Yanhusuo Chuan-niuxi Rouqui Niuxi Dahuang Duzhong
3,317 (17.2%) 3,112 (16.2%) 2,648 (13.7%) 2,252 (11.7%) 2,215 (11.5%) 1835 (9.5%) 1810 (9.4%) 1835 (9.5%) 1,690 (8.8%) 1,613 (8.4%)
4. Neurologic diseases, total prescriptions n = 16,318, n (%)
Ganjiang Dahuang Fuling Hsihsin Baizhu Huangqi Rouqui Gancao Quizhi Suanzaoren
2,864 (17.6%) 2,433 (14.9%) 2,179 (13.4%) 1822 (11.2%) 1,545 (9.5%) 1,515 (9.3%) 1,435 (8.8%) 1,414 (8.7%) 1,390 (8.5%) 1,357 (8.3%)(8.3%)
5. Cardiovascular diseases, total prescriptions n = 12,387, n (%)
Ganjiang Baizhu Dahuang Fuling Quizhi Danshen Huangqi Rouqui Hsihsin Dangqui
1915 (15.5%) 1,543 (12.5%) 1,465 (11.8%) 1,427 (11.5%) 1,352 (10.9%) 1,299 (10.5%) 1,283 (10.4%) 1,114 (9.0%) 1,100 (8.9%) 903 (7.3%)
6. Headache, total prescription n = 12,063, n (%)
Hsihsin Dahuang Ganjiang Fuling Quizhi Baizhu Yanhusuo Chuanxiong Gancao Gegen
1980 (16.4%) 1707 (14.2%) 1,652 (13.7%) 1,630 (13.5%) 1,415 (11.7%) 1,353 (11.2%) 1,166 (9.7%) 1,090 (9.0%) 1,000 (8.3%) 933 (7.7%)
TCM, traditional Chinese medicine. The detailed identifications of the mentioned TCM herbal drugs, including Latin names and scientific names, are listed in supplementary Table S5.
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In addition to Fuzi and single TCM herbal pairs, we conducted
market basket analysis to find the association rules among Fuzi and
multiple TCM herbs. For example, Fuzi–Hsihsin–Dahuang was a
commonTCMpair with the support of 5.1% (antecedent confidence,
0.456; consequent confidence, 0.342; Lift, 3.065) in neurologic
diseases (Table 5). The association rules could be interpreted that
5.1% of Fuzi prescriptions for neurologic diseases, TCM doctors
combined Hsihsin and Dahuang (Figure 3). Also, 45.6% of
prescriptions comprising Fuzi and Hsihsin included Dahuang
(Table 5 and Figure 3). 34.2% of prescriptions comprising
Fuzi and Dahuang also combined with Hsihsin (Table 5
and Figure 3). The Fuzi–Hsihsin–Dahuang combination
was also used in gastrointestinal diseases and headache
(Table 5). Besides, the Fuzi–Fuling–Ganjiang was another
common herbal pair used in neurologic diseases with the
support of 5.4% (antecedent confidence, 0.306; consequent
confidence, 0.403; Lift, 2.304).
For gastrointestinal diseases, Dahuang, Hsihsin, Fuling, and
Banxia were four herbs common in two combinations (Table 5),
and even in three combinations (Banxia–Dahuang–Hsihsin) to form
herbal pairs with Fuzi. For cardiovascular diseases,
Fuzi–Fuling–Baizhu herbal pair had a support value of 5.4% and
a lift value of 3.749. Fuzi–Fuling–Baizhu herbal pair was also
commonly applied in rheumatological diseases and headaches
(Table 5). There was no specific TCM pair for gynecologic
diseases gained the support value above 5%. These findings
could help Western doctors and researchers to understand the
association rules among multiple TCM herbs in specific
clinical conditions.
DISCUSSION
Tseng andChang proposed that new correlations of TCM herbs
could be established by big data analysis, which could trigger
further studies from bench to bedside and bring more
innovation into clinical practices (Tseng and Chang, 2019).
For the first time, we performed AI and data mining methods
to generate new knowledge for the modern clinical use of Fuzi
and Fuzi-based formulas. Some may argue that Fuzi has
become less and less important in modern TCM practice
because of its toxicity. However, giving 10% of the study
cohort with at least one prescription of Fuzi or Fuzi-based
formulas, we insist that Fuzi and Fuzi-based formulas is still an
integral and crucial TCM herb. Several new information
proposed by the investigation are discussed as follows.











Fuzi–Hsihsin–Mahuang Hsihsin Mahuang 0.096 0.349 0.655 2.378
2. Gastrointestinal diseases
Fuzi–Banxia–Dahuang Banxia Dahuang 0.103 0.653 0.355 2.254
Fuzi–Fuling–Dahuang Fuling Dahuang 0.091 0.470 0.313 1.623
Fuzi–Hsihsin–Dahuang Hsihsin Dahuang 0.143 0.689 0.494 2.378
Fuzi–Banxia–Fuling Banxia Fuling 0.093 0.590 0.482 3.057
Fuzi–Banxia–Hsihsin Banxia Hsihsin 0.097 0.614 0.466 2.955
Fuzi–Hsihsin–Fuling Hsihsin Fuling 0.076 0.364 0.392 1.889
3. Rheumatological diseases
Fuzi–Fuling–Baizhu Fuling Baizhu 0.093 0.585 0.687 4.309
4. Neurologic diseases
Fuzi–Hsihsin–Dahuang Hsihsin Dahuang 0.051 0.456 0.342 3.065
Fuzi–Fuling–Ganjiang Fuling Ganjiang 0.054 0.306 0.403 2.304
5. Cardiovascular diseases
Fuzi–Fuling–Baizhu Fuling Baizhu 0.054 0.432 0.467 3.749
6. Headache
Fuzi–Hsihsin–Dahuang Hsihsin Dahuang 0.054 0.331 0.391 2.398
Fuzi–Fuling–Baizhu Fuling Baizhu 0.063 0.563 0.468 4.205
The association rules were demonstrated in the following three measures: support, confidence, and lift. 1) The “support” was the relative frequency that the rule showed up in the given
dataset. 2) The “confidence”measured the reliability of the inferencemade by a rule. For example, an association rule X (antecedent factor) to Y (consequent factor) was established by the
estimate of the conditional probability of Y given X (antecedent confidence) or X given Y (consequent confidence), and high confidence indicated a strong association rule. 3) The “lift” was
the likelihood of prescribing both drugs compared with a single drug. Lift value above one means there was a positive correlation between the two drugs. The higher the lift value, the more
likely the two drugs were to be prescribed together. The detailed identifications of the mentioned TCM herbal drugs, including Latin names and scientific names, are listed in
Supplementary Table S5.
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Modern Clinical Applications of Fuzi and
Fuzi-Based Formulas
Contradictory to previous reports tand knowledge, this study showed
that the prescriptions of Fuzi were not limited to cardiovascular and
rheumatologic diseases, which were emphasized in ancient TCM
books. Interestingly, the use of Fuzi in pulmonary, gastrointestinal,
and neurologic diseases was more recommended in modern TCM
doctors (Figure 2). Our results also revealed that Fuzi and Fuzi-based
formulas had modern clinical indications which had never been
reported (Table 1). Further, we found that some TCM doctors did
not like the fixed ratio of Fuzi-based formulas, but preferred to
formulate different proportions of individual TCM herbs. For
example, the commercial products of Mahuang–Fuzi–Hsihsin
Tang were frequently prescribed for pulmonary diseases (Table 1).
Through market basket analysis, Fuzi–Hsihsin–Mahuang was also
selected as an important herbal pair with a support value of 9.6% (Lift,
2.379) for pulmonary diseases (Table 5). The results indicate that the
proportion of Fuzi,Hsihsin, andMahuang for pulmonary disease is an
important topic worth further studying.
After TCM was integrated into the Western medical system, the
combined use of medicine has become an important issue.
Understanding the patients’ comorbidities diagnosed by Western
doctors also helps TCM doctors to evaluate and prescribe suitable
TCM formulas more comprehensively. From this perspective, TCM
doctors should be concerned about possible synergic effects and
drug–drug interaction while prescribing Fuzi. Our result provided
such practical information; for example, long-term Fuzi users
frequently suffered from osteoarthritis, peptic ulcers, hypertension,
andCOPDwith the use ofNSAIDs, antacids, anti-hypertensive drugs,
and COPD inhalants (Table 2 and 3). From another perspective, the
FIGURE 2 | Clinical indications of prescriptions of Fuzi and Fuzi-based formulas from TCM doctors in systematic categories. The percentage of total Fuzi-related
prescription numbers for indicated diseases is shown in parentheses.
FIGURE 3 | The interpretation example of the association rules of
Fuzi–Dahuang–Hsihsin herbal pair derived from market basket analysis.
The association rules were demonstrated in the following three measures:
support, confidence, and lift. 1) The “support” was the relative
frequency that the rule showed up in the given dataset. 2) The
“confidence” measured the reliability of the inference made by a rule. For
example, an association rule X (antecedent factor) to Y (consequent
factor) was established by the estimate of the conditional probability of Y
given X (antecedent confidence) or X given Y (consequent confidence),
and high confidence indicated a strong association rule. 3) The “lift” was
the likelihood of prescribing both drugs compared with a single drug. Lift
value above one means there was a positive correlation between the two
drugs. The higher the lift value, the more likely the two drugs were to be
prescribed together.
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results also indicated that some patients might seek TCM as
complementary therapy on top of routine Western medical
treatments. Therefore, Western doctors also need to understand
the relevant precautions of TCM drugs combined with Western
medications.
Rediscover the Practical Fuzi-Based
Formulas Hidden in Ancient Traditional
Chinese Medicine Books
Market basket analysis wasmostly applied to identify concurrent-drug
patterns and food consumption. We are first to demonstrate the
practicality of market basket analysis in evaluating TCM herbal pairs
ofmore than twodrugs. The association rules derived from themarket
basket analysis lifted the veil of the combination strategies in TCM.
We proposed with scientific data that Fuzi–Dahuang–Hsihsin
herbal pair was useful in headache, neurological, and
gastrointestinal diseases (Table 5). In a TCM book named Jin
Gui Yao Lue (Zhang and Wilms, 2012), which was also called
Essential Prescriptions of the Golden Cabinet, initially written by
Zhongjing Zhang, we could find this formula to support our
analysis. The formula was called Dahuang-Fuzi Tang, a decoction
comprised of Dahuang (9 g), processed Fuzi (10 g), and Hsihsin
(3 g), prescribed to patients who suffered from abdominal
coldness and spasm, migraine, sciatica, and gallbladder and
renal stones. However, Dahuang-Fuzi Tang has not become a
commercial TCM product and has not been discussed
scientifically. We suggest it is a potential botanic drug candidate.
We also founded that Fuzi–Fuling pair was prescribed in many
conditions (Table 4). Fuling can expel inappropriate accumulation of
water by TCM theory and previous clinical investigation (Huang L.
et al., 2018). Thus, Fuzi–Fuling pairmay reduce edema, improve heart
failure, and enhance the diuretic effect. Through market basket
analysis, Fuzi–Fuling pair was frequently combined with Ganjiang,
Baizhu, Banxia, or Hsihsin (Table 5). Among these pairs, the
Fuzi–Fuling–Ganjiang pair might be simplified and modified from
Fuling-Sini Tang used in HF patients or common-cold patients
suffering from sweating and irritability. The Fuzi–Fuling–Baizhu
pair can be simplified from Jenwu Tang. One commerce product,
the Scarlet pill (Zhang and Wilms, 2012), a formula for cold
extremities and abdominal pain, in which Wutou (Aconiti Radix)
replaced Fuzi, supported the benefit of combinations of Fuzi, Fuling,
Banxia, and Hsihsin. These findings enhance the connection between
TCM books and current clinical practices and may accelerate the
practical commercial Fuzi-based formulas into products.
The Discovery of Innovative Fuzi-Related
Herbal Pairs
The current study discovered some innovative Fuzi-related
herbal pairs in specific clinical conditions, which were
unknown to most Western researchers. This information,
which was extracted from the big database, overcame the
knowledge gap in the Western researchers’ minds about
using TCM herbs. We not only ignited scientific TCM
issues but also proposed issues that need further scientific
evidence.
For example, Suanzaoren (Ziziphi Spinosae Semen), which
was well known to regulate the central nervous system,
improve memory function, depression, and sleep (Li et al.,
2013), was found to form a Fuzi–Suanzaoren herbal pair for
the neurologic diseases (Table 4). The mechanisms and
synergistic effect of Fuzi and Suanzaoren in treating
neurologic disease will become a research interest. Another
innovative combination that was discovered in this study was
Fuzi–Danshen (Salviae Miltiorrhizae Radix et Rhizoma) herbal
pair. Danshen was effective in antioxidative, anti-
inflammatory, endothelial protective, myocardial protective,
anticoagulation, vasodilation, and anti-atherosclerosis
mechanisms (Ren et al., 2019). The potentially synergic
effect of Fuzi–Danshen herbal pair in cardiovascular
diseases has not yet been investigated. Similarly, the
cardiovascular effects of Fuzi–Huangqi or Fuzi–Dangqui
(Angelicae Sinensis Radix) are also worthy of further research.
Fuzi in combination with Yanhusuo (Corydalis Rhizoma),
Chuan-niuxi (Cyathulae Radix), Niuxi (Achyranthis Bidentatae
Radix), or Duzhong (Eucommiae Cortex) were frequently
prescribed for rheumatologic diseases (Table 4). Among them,
Yanhusuo had an antinociceptive effect (Choi et al., 2012). Niuxi
and Chuan-niuxi were showed to protect articular chondrocytes
(Xu et al., 2017), and Duzhong exhibited anti-osteoarthritic
effects (Choi et al., 2020). In TCM theory, these drugs can
enhance the effect of Fuzi in treating rheumatologic diseases,
but the mechanism was not well understood. The mentioned
Fuzi-related herbal pairs can become the next Fuzi-based
botanical drugs, as Qili-qiangxin capsules (Tao et al., 2013)
and Shenfu injection (Song et al., 2012) were two successful
examples derived from Fuzi–related herbal pairs. The current
study expanded the research field of Fuzi and the possibility of
new drug development.
Strength and Limitation
The major strength of this study is that it is the first time to
evaluate the modern clinical use of Fuzi and Fuzi-based
formulas using a large population-based cohort with AI or
data mining techniques such as market basket analysis.
However, the study results also had some limitations. First,
some of the medical records of patients who took TCM
decoction but not commercial TCM granular powders were
not documented in the Taiwan NHI database. That was because
NHI did not pay for TCM decoction in the current TCM system,
and patients must pay for themselves. Therefore, the prevalence
of Fuzi use might be underestimated. Second, although the Fuzi
commercial products were mostly manufactured according to
herbal pharmacopeia, the dosage of each commercial powder
prescribed by TCM doctors was not standardized and
documented in the Taiwan NHI database. Third, we only
evaluated the numbers of prescriptions, the prevalence of
comorbidities, and concurrent Western medications. The
dose-response relationship could not be precisely evaluated.
Finally, we evaluated the TCM pairs only with the support
values above 5% in the market basket analysis. There might be
some interesting TCM pairs with a low prevalence rate that were
not discovered.
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CONCLUSION
The current study is the first to demonstrate the usefulness of
market basket analysis in evaluating the combination principle of
TCM herbs. We provide epidemiologic evidence on the clinical
applications of Fuzi and Fuzi-based formulas in the healthcare
system dominated by Western medicine. Our study also supports
the traditional usage of Fuzi-based formulas and inspires future
pharmacological, observational, and clinical studies of Fuzi-
related herbal pairs. In sum, the results light up the road to
the development of new Fuzi-based botanic drugs.
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